Eczematous Eruption During Bimekizumab Treatment in a Psoriatic Patient Previously Treated with Secukinumab
Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
Authors
- Lorenzo Maria Pinto (ORCID: https://orcid.org/0009-0005-1746-2708)
- Giacomo Caldarola (ORCID: https://orcid.org/0000-0002-8837-9232)
- Clara De Simone (ORCID: https://orcid.org/0000-0002-0898-0045)
- Alessandra D’Amore
- Ketty Peris (ORCID: https://orcid.org/0000-0002-5237-0463)
- Gennaro Marco Falco (ORCID: https://orcid.org/0009-0001-1219-9008)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Skin Health and Disease
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1002/ski2.371
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.72